Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

被引：6
|
作者：
Antonarakis, Emmanuel S.
Goh, Jeffrey C.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
De Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[3] Univ Hosp Bordeaux, Bordeaux, France
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Hosp Duran & Reynals, Inst Catalan Oncol, Barcelona, Spain
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Docrates Canc Ctr, Helsinki, Finland
[8] Chiba Canc Ctr, Chiba, Japan
[9] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[10] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[11] MSD China, Beijing, Peoples R China
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
216
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Keynote-199: Updated analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel
    Goh, Jeffrey C.
    Antonarakis, Emmanuel S.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    de Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian H.
    de Bono, Johann S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 48 - 49
  • [2] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Goh, Jeffrey C. H.
    Ojamaa, Kristiina
    Rodriguez, Jose Maria Piulats
    Drake, Charles G.
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.
    Goh, Jeffrey C.
    Piulats Rodriguez, Jose Maria M.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Rodriguez, Jose Maria M. Piulats
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    Qiu, Ping
    Suttner, Leah
    Cristescu, Razvan
    Marton, Matthew John
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Biomarker analysis of men with enzalutamide (enza)resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) plus enza in KEYNOTE-199
    Graff, J. N.
    Tagawa, S.
    Hoimes, C.
    Gerritsen, W.
    Vaishampayan, U. N.
    Elliott, T.
    Hwang, C.
    Ten Tije, A. J.
    Omlin, A. G.
    McDermott, R. S.
    De Wit, R.
    Qiu, P.
    Poehlein, C.
    Kim, J.
    Suttner, L.
    Cristescu, R.
    Marton, M. J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S383 - S383
  • [6] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [9] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345